Navigation Links
Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
Date:10/7/2009

CRANBURY, N.J., Oct. 7 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced today that groundbreaking cancer research scientist Robert A. Weinberg, Ph.D., a founding member of the Whitehead Institute for Biomedical Research and a Professor of Biology at MIT, has joined the company's Scientific Advisory Board.

Widely recognized for his discoveries of the first human oncogene (the ras oncogene that causes normal cells to form tumors), and the isolation of the first known tumor suppressor gene -- the Rb gene, Dr. Weinberg has long been recognized as a pioneer in cancer research.

"We are delighted to welcome Dr. Weinberg to our Scientific Advisory Board," commented Dr. Robert Shorr, CEO, of Cornerstone Pharmaceuticals. "Dr. Weinberg's accomplishments in cancer research are monumental and we believe his experience, guidance and vision will be of tremendous benefit to the Company."

Cornerstone Pharmaceuticals is currently recruiting patients with solid tumors to advance multiple Phase I/II human clinical trials of CPI-613, its lead drug to emerge from the company's Altered Energy Metabolism Directed (AEMD) technology platform. CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types. CPI-613 is being evaluated in a Phase I/II single agent trial for patients who have failed all other therapy as well as in a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients determined to be treated with gemcitabine. Pancreatic cancer, like many solid tumors, typically has a poor prognosis, spreads rapidly and often goes undetected in its early stages. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

"I am pleased to join Cornerstone Pharmaceuticals as a member of its Scientific Advisory Board and look forward to
'/>"/>

SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 ... healthcare funding changes brought about by the ... both reimbursement and prescribing of pharmaceutical therapies. ... (MCOs) cover beneficiaries through new regulations and ... is occurring in the health exchanges—state-based marketplaces ...
(Date:7/31/2014)... 2014 Hovione today announced that its ... successfully passed a pre-approval inspection by the US Food and ... the FDA Consumer Safety Officer, Ms. Britanny Terhar , ... July and concluded on the 25 th . The ... and guidelines of Good Manufacturing Practices (GMP) and no Form ...
(Date:7/31/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), Gilead (Nasdaq: GILD - Free ... ), AbbVie (NYSE: ABBV - Free Report ) and ... Today, Zacks is promoting its ,Buy, stock recommendations. Get ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... N.J. , Aug. 4 ... Co., Ltd, (collectively, "Daiichi Sankyo") have reached an agreement ... settle their patent litigation involving Apotex,s challenge to Daiichi ... "the ,821 patent") covering Evoxac® (cevimeline HCl).  Under the ...
... Cardica, Inc. (Nasdaq: CRDC ) today announced that it will release ... Tuesday, August 17, 2010 , after the markets close. Cardica,s management will host a conference ... update on the company,s business. , , , ... , , , ...
Cached Medicine Technology:Daiichi Sankyo Settled Patent Litigation for Evoxac® 2Cardica to Announce Fiscal 2010 Fourth Quarter and Year End Financial Results on Tuesday, August 17, 2010 2
(Date:7/31/2014)... To further educate the public, The Rothenberg ... safety information regarding leaving children in hot vehicles: , ... consequences. Because a child’s body can heat up three ... children alone in a hot vehicle puts them at ... Statistics of Children Left Alone in a Car , ...
(Date:7/31/2014)... Texas (PRWEB) July 31, 2014 ... Austin-based physicians Tracey Haas and Tim Gueramy, announced the ... Docbook Enterprise. , According to Dr. Tim Gueramy, CEO ... their solution because physician leaders from each one had ... saw a huge benefit for their respective organizations to ...
(Date:7/31/2014)... Johns Hopkins have developed blood and saliva tests that ... a substantial number of patients. The tests screen for ... cancer cells lingering in the mouth or other parts ... published in the July 31 issue of JAMA ... is a window of opportunity in the year after ...
(Date:7/31/2014)... Rich Dad® Education , a leader in financial ... for Humanity. The yard sale was a success. In just ... proceeds donated to Habitat for Humanity of Lee and Hendry ... were donated to the Habitat for Humanity ReStore thrift store ... , Of the over $650, roughly $30 was raised ...
(Date:7/31/2014)... -- With the World Health Organization reporting that the ... risen to 729, the U.S. Centers for Disease ... for,the region. The "Level 3 travel advisory" urges ... Guinea, Liberia and Sierra Leone -- be avoided. ... West Africa," CDC Director Dr. Tom Frieden told reporters ...
Breaking Medicine News(10 mins):Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Physician Demand for Integrated Communication Platform Drives DocbookMD Growth 2Health News:Blood and saliva tests help predict return of HPV-linked oral cancers 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2
... July 14, 2009 Infectious disease specialists at UT Southwestern ... severe Staphylococcus aureus infections, providing crucial insight ... to this pathogen and opening new doors for improved therapeutic ... on understanding precisely what the bacterium S aureus does ...
... , DENVER, July 13 DaVita Inc. (NYSE: ... with chronic kidney disease (CKD), today announced Mahesh Krishnan, MD, MPH has ... July 13, 2009. , , (Logo: ... is recognized as a leader in clinical trials for drugs and devices. ...
... , DENVER, July 13 ... Luncheon will be held in Denver July 23 at the ... luncheon, sponsored by MillerCoors, will honor and welcome Her Excellency, ... annual fundraising event raises awareness of global healthcare needs and ...
... , ... The Extraordinary Leader, performance thought leaders John Zenger and Joseph Folkman revealed the 16 ... first book,s publication, they have discovered, through an extensive study conducted over four years, that ... ...
... A new study of the cognitive processes involved with ... temptation than active resistance to temptation. Using ... given the chance to gain money dishonestly by lying ... activity when telling the truth, implying that extra cognitive ...
... , , , Gail ... Sector in Current Economic Climate , , ... Cross will be the featured speaker at a National Press Club Luncheon on Tuesday, ... through Turbulent Economic Times." , , (Logo: ...
Cached Medicine News:Health News:Researchers map how staph infections alter immune system 2Health News:Researchers map how staph infections alter immune system 3Health News:DaVita Clinical Research Appoints Mahesh Krishnan as Vice President 2Health News:DaVita Clinical Research Appoints Mahesh Krishnan as Vice President 3Health News:Project C.U.R.E. and MillerCoors to Welcome the First Lady of Ghana to Colorado for First Ladies' Luncheon in Denver 2Health News:Project C.U.R.E. and MillerCoors to Welcome the First Lady of Ghana to Colorado for First Ladies' Luncheon in Denver 3Health News:Project C.U.R.E. and MillerCoors to Welcome the First Lady of Ghana to Colorado for First Ladies' Luncheon in Denver 4Health News:Zenger Folkman Releases Latest Book: The Inspiring Leader: Unlocking the Secrets of How Extraordinary Leaders Motivate 2Health News:Zenger Folkman Releases Latest Book: The Inspiring Leader: Unlocking the Secrets of How Extraordinary Leaders Motivate 3Health News:Neuroimaging suggests that truthfulness requires no act of will for honest people 2Health News:Neuroimaging suggests that truthfulness requires no act of will for honest people 3Health News:American Red Cross President to Address National Press Club Luncheon 2
... the state of the art product for ... articular surfaces does not restrict natural movement, ... a wide area of contact between the ... of cement create a homogeneous cement mantle ...
... The TC-PLUS Solution tricompartmental total knee ... with knee arthroplasty. State-of-the-art design and manufacturing ... achieve optimum biomechanical function as well as ... polyethylene tibial insert to keep wear to ...
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The modern design allows extremely sparing resections. The components exhibit an anatomical geometry t...
... System is a long term, quality solution ... in both posterior stabilized and anatomically correct ... provides the flexibility needed to address patients' ... of identification keeps the user in mind ...
Medicine Products: